Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 18/20 | 0.72 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.58 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923576 | 0.84 | GRM4 (1.00) | GRM4TRPA1KCNQ3KCNQ2KCNQ1 | |
| SCHEMBL2360210 | 0.82 | GRM4 (1.00) | GRM4 | |
| SCHEMBL29496460 | 0.82 | GRM4 (1.00) | GRM4 | |
| SCHEMBL6923707 | 0.78 | GRM4 (1.00) | GRM4TRPA1 | |
| SCHEMBL6922868 | 0.77 | GRM4 (0.70) | GRM4 | |
| SCHEMBL6923487 | 0.75 | GRM4 (0.64) | GRM4TRPA1 | |
| SCHEMBL19793215 | 0.73 | GRM4 (1.00) | GRM4TRPA1KCNQ3KCNQ2KCNQ1 | |
| SCHEMBL6922229 | 0.73 | GRM4 (0.58) | GRM4TRPA1 | |
| SCHEMBL19794683 | 0.72 | GRM4 (1.00) | GRM4TRPA1 | |
| SCHEMBL20901588 | 0.71 | GRM4 (0.50) | GRM4TRPA1KCNQ3KCNQ2KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163015-B2 | Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130096110-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011100607-A1 | PYRAZOLOPYRIDINE, PYRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOUNDS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096110-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | GRM4 1/4885TRPA1 479/4885KCNQ3 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.